# MEF2D

## Overview
The MEF2D gene encodes the myocyte enhancer factor 2D protein, a transcription factor that plays a pivotal role in regulating gene expression across various biological processes, including muscle development, neuronal differentiation, and immune responses. As a member of the MEF2 family, the MEF2D protein is characterized by a MADS-box domain and a MEF2-specific domain, which are essential for its DNA-binding and dimerization functions (Chen2021Purification). MEF2D is involved in both nuclear and mitochondrial activities, influencing cellular processes such as proliferation, differentiation, and apoptosis (She2011Direct; Estrella2015MEF2D). The gene undergoes alternative splicing, resulting in multiple isoforms that may have distinct functional roles (Gönczi2023Alternatively). MEF2D's activity is modulated by post-translational modifications, including phosphorylation, acetylation, and sumoylation, which affect its stability and function (Gönczi2023Alternatively). The protein's involvement in critical cellular pathways underscores its significance in both normal physiology and disease states, such as cancer and neurodegenerative disorders (Sadras2020MEF2D; Arosio2016MEF2D).

## Structure
The MEF2D protein is a transcription factor characterized by a MADS-box domain and a MEF2-specific domain, which are essential for its DNA-binding and dimerization functions (Chen2021Purification). The N-terminal region of MEF2D is crucial for DNA binding, playing a significant role in its function as a transcription factor and in leukemogenesis (Chen2021Purification). The protein can form homodimers or heterodimers with other MEF2 family members, facilitating its role in transcription regulation.

MEF2D undergoes alternative splicing, resulting in multiple isoforms that may have distinct functional roles (Gönczi2023Alternatively). The β-domain of MEF2D is an acidic region that enhances transcriptional activity by serving as an interaction element for higher-order assembly. This domain can adopt both ordered and disordered conformations, influencing MEF2D's ability to form nuclear condensates and cytosolic aggregates, which are associated with increased transcriptional activity and early myotube development (Gönczi2023Alternatively).

Post-translational modifications such as phosphorylation, acetylation, and sumoylation influence MEF2D's activity and stability, although specific details on these modifications are not provided in the context. The structural dynamics of MEF2D, particularly the β-domain, play a crucial role in its function during myogenesis (Gönczi2023Alternatively).

## Function
MEF2D (myocyte enhancer factor 2D) is a transcription factor that plays a crucial role in various cellular processes in healthy human cells. It is involved in regulating gene expression during muscle development, neuronal differentiation, and immune responses. MEF2D is active in both the nucleus and mitochondria, where it binds to DNA sequences to activate or repress target genes, influencing cellular processes like proliferation, differentiation, and apoptosis (She2011Direct; Estrella2015MEF2D).

In neuronal cells, MEF2D is localized in the mitochondria, where it regulates the expression of the NADH dehydrogenase 6 (ND6) gene, a component of the oxidative phosphorylation complex I. This regulation is essential for maintaining complex I activity, ATP production, and protecting neurons from stress-induced death (She2011Direct). Disruption of MEF2D function can lead to decreased complex I activity and increased oxidative stress, contributing to neurodegenerative diseases like Parkinson's disease (She2011Direct).

In cardiomyocytes, MEF2D is crucial for cell cycle regulation and survival. It modulates the PI3K/Akt signaling pathway, influencing cell cycle progression and apoptosis. MEF2D deficiency in neonatal cardiomyocytes triggers cell cycle re-entry and programmed cell death, highlighting its role in maintaining cardiomyocyte homeostasis (Estrella2015MEF2D).

## Clinical Significance
MEF2D gene alterations are implicated in several diseases, particularly in various forms of cancer. In B-cell acute lymphoblastic leukemia (B-ALL), MEF2D fusions occur in approximately 5% of cases and are associated with poor outcomes. These fusions involve the N-terminus of MEF2D with partners like BCL9 and HNRNPUL1, leading to oncogenic signaling that promotes malignant B-cell transformation (Sadras2020MEF2D; Tange2020Staurosporine). MEF2D rearrangements are considered founding alterations in a specific subgroup of B-ALL, characterized by a distinct gene expression profile and poor prognosis (Gu2016Genomic).

In colorectal cancer, MEF2D is overexpressed, correlating with metastasis and poor prognosis. This overexpression enhances cancer cell migration and invasion, suggesting a role in cancer progression (Su2016MEF2D). MEF2D is also implicated in neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), where its mRNA levels are upregulated in patients, although protein levels remain unchanged. This suggests a disruption in MEF2D pathways, potentially contributing to disease pathogenesis (Arosio2016MEF2D). These findings highlight the clinical significance of MEF2D in both oncological and neurological contexts.

## Interactions
MEF2D interacts with various proteins and nucleic acids, playing a significant role in transcriptional regulation. It forms complexes with histone deacetylase 1 (HDAC1) and the histone acetyltransferase p300, which are crucial for regulating gene expression. In THP-1 cells, MEF2D acts as a scaffold protein, interacting with HDAC1 to repress SOD3 expression under basal conditions. Upon treatment with TPA, MEF2D facilitates the dissociation of HDAC1 and the association of p300 with the SOD3 promoter, enhancing SOD3 expression (Ichihara2018The).

In the context of muscle cells, MEF2D interacts with the scaffold protein mAKAPβ and calcineurin (CaN). This interaction is essential for the dephosphorylation of MEF2D at Ser-444, which switches MEF2D's binding from the co-repressor HDAC5 to the co-activator p300, promoting transcriptional activation (Li2019Muscle).

MEF2D also plays a role in the DNA damage response by forming a complex with ATM kinase. ATM phosphorylates MEF2D at specific sites, which is necessary for MEF2D activation and neuronal survival following DNA damage (Chan2014ATMDependent).


## References


[1. (Sadras2020MEF2D) Teresa Sadras and Markus Müschen. Mef2d fusions drive oncogenic pre-bcr signaling in b-all. Blood Cancer Discovery, 1(1):18–20, June 2020. URL: http://dx.doi.org/10.1158/2643-3249.bcd-20-0078, doi:10.1158/2643-3249.bcd-20-0078. This article has 3 citations.](https://doi.org/10.1158/2643-3249.bcd-20-0078)

[2. (Gönczi2023Alternatively) Mónika Gönczi, João M. C. Teixeira, Susana Barrera-Vilarmau, Laura Mediani, Francesco Antoniani, Tamás Milán Nagy, Krisztina Fehér, Zsolt Ráduly, Viktor Ambrus, József Tőzsér, Endre Barta, Katalin E. Kövér, László Csernoch, Serena Carra, and Monika Fuxreiter. Alternatively spliced exon regulates context-dependent mef2d higher-order assembly during myogenesis. Nature Communications, March 2023. URL: http://dx.doi.org/10.1038/s41467-023-37017-7, doi:10.1038/s41467-023-37017-7. This article has 3 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-37017-7)

[3. (Ichihara2018The) Mari Ichihara, Tetsuro Kamiya, Hirokazu Hara, and Tetsuo Adachi. The mef2a and mef2d function as scaffold proteins that interact with hdac1 or p300 in sod3 expression in thp-1 cells. Free Radical Research, 52(7):799–807, May 2018. URL: http://dx.doi.org/10.1080/10715762.2018.1475730, doi:10.1080/10715762.2018.1475730. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/10715762.2018.1475730)

[4. (Gu2016Genomic) Zhaohui Gu, Michelle Churchman, Kathryn Roberts, Yongjin Li, Yu Liu, Richard C. Harvey, Kelly McCastlain, Shalini C. Reshmi, Debbie Payne-Turner, Ilaria Iacobucci, Ying Shao, I-Ming Chen, Marcus Valentine, Deqing Pei, Karen L. Mungall, Andrew J. Mungall, Yussanne Ma, Richard Moore, Marco Marra, Eileen Stonerock, Julie M. Gastier-Foster, Meenakshi Devidas, Yunfeng Dai, Brent Wood, Michael Borowitz, Eric E. Larsen, Kelly Maloney, Leonard A. Mattano Jr, Anne Angiolillo, Wanda L. Salzer, Michael J. Burke, Francesca Gianni, Orietta Spinelli, Jerald P. Radich, Mark D. Minden, Anthony V. Moorman, Bella Patel, Adele K. Fielding, Jacob M. Rowe, Selina M. Luger, Ravi Bhatia, Ibrahim Aldoss, Stephen J. Forman, Jessica Kohlschmidt, Krzysztof Mrózek, Guido Marcucci, Clara D. Bloomfield, Wendy Stock, Steven Kornblau, Hagop M. Kantarjian, Marina Konopleva, Elisabeth Paietta, Cheryl L. Willman, Mignon L. Loh, Stephen P. Hunger, and Charles G. Mullighan. Genomic analyses identify recurrent mef2d fusions in acute lymphoblastic leukaemia. Nature Communications, November 2016. URL: http://dx.doi.org/10.1038/ncomms13331, doi:10.1038/ncomms13331. This article has 206 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms13331)

[5. (She2011Direct) Hua She, Qian Yang, Kennie Shepherd, Yoland Smith, Gary Miller, Claudia Testa, and Zixu Mao. Direct regulation of complex i by mitochondrial mef2d is disrupted in a mouse model of parkinson disease and in human patients. Journal of Clinical Investigation, 121(3):930–940, March 2011. URL: http://dx.doi.org/10.1172/jci43871, doi:10.1172/jci43871. This article has 135 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci43871)

[6. (Chen2021Purification) Zhiming Chen, Qianqian Wang, Hao Zhang, Xiaodan Ma, Wenyu Wu, Nuo Cheng, Ji Zhang, Aiwu Zhou, Yuwen Li, and Guoyu Meng. Purification, crystallization, and x-ray diffraction analysis of myocyte enhancer factor 2d and dna complex. Protein Expression and Purification, 179:105788, March 2021. URL: http://dx.doi.org/10.1016/j.pep.2020.105788, doi:10.1016/j.pep.2020.105788. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.pep.2020.105788)

[7. (Estrella2015MEF2D) Nelsa L. Estrella, Amanda L. Clark, Cody A. Desjardins, Sarah E. Nocco, and Francisco J. Naya. Mef2d deficiency in neonatal cardiomyocytes triggers cell cycle re-entry and programmed cell death in vitro. Journal of Biological Chemistry, 290(40):24367–24380, October 2015. URL: http://dx.doi.org/10.1074/jbc.m115.666461, doi:10.1074/jbc.m115.666461. This article has 31 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m115.666461)

[8. (Su2016MEF2D) Li Su, Yongli Luo, Zhi Yang, Jing Yang, Chao Yao, Feifei Cheng, Juanjuan Shan, Jun Chen, Fangfang Li, Limei Liu, Chungang Liu, Yanmin Xu, Lupin Jiang, Deyu Guo, Jesus Prieto, Matías A. Ávila, Junjie Shen, and Cheng Qian. Mef2d transduces microenvironment stimuli to zeb1 to promote epithelial–mesenchymal transition and metastasis in colorectal cancer. Cancer Research, 76(17):5054–5067, August 2016. URL: http://dx.doi.org/10.1158/0008-5472.CAN-16-0246, doi:10.1158/0008-5472.can-16-0246. This article has 71 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.CAN-16-0246)

[9. (Li2019Muscle) Jinliang Li, Shania Aponte Paris, Hrishikesh Thakur, Michael S. Kapiloff, and Kimberly L. Dodge-Kafka. Muscle a-kinase–anchoring protein-β–bound calcineurin toggles active and repressive transcriptional complexes of myocyte enhancer factor 2d. Journal of Biological Chemistry, 294(7):2543–2554, February 2019. URL: http://dx.doi.org/10.1074/jbc.ra118.005465, doi:10.1074/jbc.ra118.005465. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.ra118.005465)

[10. (Tange2020Staurosporine) Naoyuki Tange, Fumihiko Hayakawa, Takahiko Yasuda, Koya Odaira, Hideyuki Yamamoto, Daiki Hirano, Toshiyasu Sakai, Seitaro Terakura, Shinobu Tsuzuki, and Hitoshi Kiyoi. Staurosporine and venetoclax induce the caspase-dependent proteolysis of mef2d-fusion proteins and apoptosis in mef2d-fusion (+) all cells. Biomedicine &amp; Pharmacotherapy, 128:110330, August 2020. URL: http://dx.doi.org/10.1016/j.biopha.2020.110330, doi:10.1016/j.biopha.2020.110330. This article has 5 citations.](https://doi.org/10.1016/j.biopha.2020.110330)

[11. (Chan2014ATMDependent) Shing Fai Chan, Sam Sances, Laurence M. Brill, Shu-ichi Okamoto, Rameez Zaidi, Scott R. McKercher, Mohd W. Akhtar, Nobuki Nakanishi, and Stuart A. Lipton. Atm-dependent phosphorylation of mef2d promotes neuronal survival after dna damage. The Journal of Neuroscience, 34(13):4640–4653, March 2014. URL: http://dx.doi.org/10.1523/JNEUROSCI.2510-12.2014, doi:10.1523/jneurosci.2510-12.2014. This article has 27 citations.](https://doi.org/10.1523/JNEUROSCI.2510-12.2014)

[12. (Arosio2016MEF2D) Alessandro Arosio, Gessica Sala, Virginia Rodriguez-Menendez, Denise Grana, Francesca Gerardi, Christian Lunetta, Carlo Ferrarese, and Lucio Tremolizzo. Mef2d and mef2c pathways disruption in sporadic and familial als patients. Molecular and Cellular Neuroscience, 74:10–17, July 2016. URL: http://dx.doi.org/10.1016/j.mcn.2016.02.002, doi:10.1016/j.mcn.2016.02.002. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.mcn.2016.02.002)